Riders on the Storm Part 3: Devices, Compounding, GLP-1 Medications, and Food By Jennifer D. Newberger & Sara W. Koblitz & Deborah L. Livornese & Dara Katcher Levy & Mark A. Tobolowsky & Kalie E. Richardson & Riëtte van Laack & Mary Bass —

https://www.thefdalawblog.com/2026/06/riders-on-the-storm-part-3-devices-compounding-glp-1-medications-and-food/?utm_source=rss&utm_medium=rss&utm_campaign=riders-on-the-storm-part-3-devices-compounding-glp-1-medications-and-food This third installment of our series analyzing the rider provisions in the fiscal year 2026 appropriations legislation continues our examination of key FDA policy directives embedded in congressional committee reports. This post focuses on provisions related to medical devices, pharmacy compounding, GLP-1 medications, and food-areas where Congress has expressed heightened interest in FDA enforcement, regulatory clarity, and patient safety. As with prior installments, these rider provisions, while non-binding, offer valuable insight into congressional priorities and potential areas of future regulatory focus for FDA-regulated industries. Riders on the Storm Part 2: The Drug Provisions June 25, 2026 By Jennifer D. Newberger & Sara W. Koblitz & Deborah L. Livornese & Dara Katcher Levy & Mark A. Tobolowsky & Kalie E. Richardson & Riëtte van Laack & Mary Bass — This is the second in our series analyzing the riders attached to the FY 2026 Labor-HHS Appropriations Bill. This installment examines the drug-related provisions, which cover a wide range of topics from accelerated approval and rare disease therapies to biosimilars and opioid regulation. The Committee’s report reflects ongoing congressional priorities while also addressing persistent industry frustrations and emerging regulatory challenges. Below, we summarize the key drug-related provisions and offer our analysis of what they may mean for sponsors, manufacturers, and the broader pharmaceutical landscape. https://www.thefdalawblog.com/2026/06/riders-on-the-storm-part-2-the-drug-provisions/ Riders on the Storm Part 1: What the FY2027 Appropriations Report Means for FDA June 24, 2026 By Jennifer D. Newberger & Sara W. Koblitz & Deborah L. Livornese & Dara Katcher Levy & Mark A. Tobolowsky & Kalie E. Richardson & Riëtte van Laack & Mary Bass — On May 1, 2026, the House Committee on Appropriations submitted House Report 119-632 to accompany H.R. 8646—the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for Fiscal Year 2027, which passed on June 4, 2026. The report serves as the Committee’s explanation of the accompanying bill, setting forth funding levels, programmatic directives, and policy priorities across the U.S. Department of Agriculture (USDA), the Food and Drug Administration (FDA), the Commodity Futures Trading Commission (CFTC), and the Farm Credit Administration (FCA). Given that of these acronyms our blog has only FDA in the title, it should come as no surprise that we are focused only on the FDA provisions, of which there are plenty—so many that we needed to split the post into three parts. The first, published today, will cover a few key provisions from the Act and the cross-product riders. Post 2 will look at the drug-specific provisions (including biosimilars). And Post 3 will look at everything else, including devices and compounding. https://www.thefdalawblog.com/2026/06/riders-on-the-storm-part-1-what-the-fy2027-appropriations-report-means-for-fda/